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Abstract
The sustenance of most solid tumors including head and neck cancers (HNCs) is strongly dependent on the pres-
ence of a functioning vascular network. In this study, we examined the acute effects of a tumor vascular disrupting
agent (VDA), 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404), in an orthotopic model of human HNC. Non-
invasive magnetic resonance imaging (MRI) was used to monitor the vascular response of orthotopic FaDu xeno-
grafts to VDA therapy. Untreated tumors showed a marked but heterogeneous pattern of enhancement after
contrast agent injection on serial T1-weighted (T1W) MR images. After VDA treatment, T2W and T1WMRI revealed
evidence of hemorrhaging and lack of functioning vessels (enhancement) within the tumor. Quantitative estimates
of relative vascular volume also showed a significant (P < .01) reduction in DMXAA-treated tumors 24 hours after
therapy compared with untreated controls. Histology and immunostaining of untreated orthotopic FaDu tumors
revealed poorly differentiated squamous cell carcinoma histology with distinctly visible CD31+ endothelial cells.
In sharp contrast, minimal CD31 staining with irregular endothelial fragments and faint outlines of blood vessels
were seen in DMXAA-treated tumor sections. CD31 immunostaining and histology also highlighted the selectivity
of vascular damage and tissue necrosis after VDA therapy with no evidence of toxicity observed in normal salivary
gland, heart, liver, and skeletal muscle tissues. Together, our results demonstrate a potent and selective vascular
disruptive activity of DMXAA in an orthotopic HNC model. Further evaluation into its antitumor effects alone and in
combination with other agents is warranted.
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Introduction
Head and neck cancers (HNCs) account for approximately 50,000
new cases of cancer in the United States and result in more than 10,000
deaths [1,2]. Advances in surgical and nonsurgical management have
improved response rates in HNC patients, but increases in long-term
survival have been modest [3]. Investigation into novel therapies could
therefore potentially provide clinical benefit in these patients who often
undergo debilitating changes in appearance, speech, and respiratory
function after aggressive surgical intervention [3].
Tumor angiogenesis is one of the hallmarks of cancer and a critical
determinant of malignant progression of most solid tumors including
HNC [4–6]. Early studies carried out in chick chorioallantoic mem-
branes have demonstrated the ability of head and neck tumor cells to
induce angiogenesis in vivo [7]. A strong association between malignant
progression and increased expression of proangiogenic and inflamma-
tory factors has also been demonstrated in HNC [8,9]. On the basis of
this knowledge, it was hypothesized that targeting the tumor vascula-
ture could be of potential therapeutic benefit in HNC, particularly in
well-vascularized squamous cell carcinomas (SCCs) of the head and
neck. To test this hypothesis, in a previous study, the activity of the
tumor vascular disrupting agent (VDA), 5,6-dimethylxanthenone-4-
acetic acid (DMXAA; ASA404), was investigated against two histologi-
cally distinct SCC xenografts implanted subcutaneously in nude mice
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[10]. The results of these studies demonstrated the potent antivascular,
antitumor activity of DMXAA against ectopic HNC xenografts [10].
Subcutaneous tumor models are easy to establish, economically feasible,
and are useful for rapid screening of therapeutic agents [11]. However,
these ectopic tumors do not truly recapitulate the biologic characteris-
tics of human cancers such as angiogenesis and metastatic potential
that are influenced by the host microenvironment [11,12]. Particularly
with vascular-targeted therapies, it is important to understand the re-
sponse of tumors within the context of their native tissue environment.
Therefore, in this study, the acute effects of DMXAA were investigated
in an orthotopic model of human HNC. Changes in vascular function
after VDA treatment were monitored using contrast-enhanced mag-
netic resonance imaging (MRI) in orthotopic FaDu xenografts. Correl-
ative histology and immunohistochemical staining of tumor sections
for the endothelial cell adhesion molecule, CD31, was also performed
to assess vascular damage after treatment. The results of this study dem-
onstrate, for the first time, potent vascular disruption by DMXAA in an
orthotopic model of human HNC.
Materials and Methods
Tumor Model
Eight- to ten-week-old athymic Foxn1nu nude mice (Harlan Labora-
tories, Indianapolis, IN) were fed food and water ad libitum and housed
in micro isolator cages under ambient light. Orthotopic tumors were
established by transcervical injection of 1 × 106 FaDu (human hypo-
pharyngeal SCC) [13] cells into the floor of the mouth of nude mice
similar to a procedure previously described by Rosenthal et al. [14]. Ex-
perimental studies were performed ∼15 to 20 days after implantation in
accordance with protocols approved by the Institutional Animal Care
and Use Committee.
Vascular Disrupting Agent Treatment
The DMXAA powder (Sigma, St. Louis, MO) was freshly dissolved
in D5W (dextrose 5%) and administered to tumor-bearing animals
through intraperitoneal injection at a dose of 25 mg/kg, 24 hours
before imaging. Untreated control animals did not receive drug or vehi-
cle injection.
Magnetic Resonance Imaging
Tumor-bearing mice were imaged in a 4.7-T/33-cm horizontal
bore magnet (GE NMR Instruments, Fremont, CA) incorporating
AVANCE digital electronics (Bruker Biospec, ParaVision 3.1.; Bruker
Medical, Billerica, MA), a removable gradient coil insert (G060; Bruker
Medical) generating a maximum field strength of 950 mT/m, and a
custom-designed 35-mm radiofrequency transreceiver coil. Isoflurane
(2%-3%; Abbott Laboratories, IL) inhalation was used to induce and
maintain anesthesia for imaging. Animals were placed in a prone posi-
tion on an MR-compatible mouse sled (Dazai Research Instruments,
Toronto, Canada) equipped with temperature and respiratory sensors
and positioned in the scanner by means of a carrier tube.
T2-weighted (T2W) images were acquired to determine extent of
tumor growth and volume using the following parameters: matrix size,
256 × 192; echo time (TE)/repetition time (TR), 40/2424 milli-
seconds; slice thickness, 1 mm; field of view (FOV), 4.8 × 3.2; number
of slices, 21; number of averages, 4; acquisition time, 4 minutes. T1-
weighted (T1W) contrast-enhanced MRI using the intravascular con-
trast agent albumin–gadopentetate dimeglumine (albumin–Gd-DTPA;
0.1 mmol/kg; University of California-San Francisco) was performed
in untreated controls and DMXAA-treated animals 24 hours after
treatment using a fast spin echo as described previously [10,15]. T1–
relaxation rates (R1 = 1/T1) were calculated as an indirect measure of
contrast agent concentration in tumor and normal tissues (muscle,
brain). Multislice relaxation rate (R1 = 1/T1) maps were obtained using
a saturation recovery, fast spin echo scan with variable TR using the
following parameters: TE, 10 milliseconds; matrix size, 128 × 96;
FOV, 3.2 × 3.2 mm; slice thickness, 1 mm; TR, 360, 500, 750,
1500, 3000, and 6000 milliseconds. For all animals, three baseline
images were acquired before contrast agent injection for the estimation
Figure 1. Monitoring growth of orthotopic HNC using MRI. Multislice T2W MR images of a nude mouse acquired on coronal and axial
planes showing orthotopic FaDu tumor growth in vivo. T2W images provided adequate contrast to allow clear delineation of the tumor
from surrounding tissues. Arrows indicate tumor; B, brain.
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of precontrast T1 values. Albumin–(Gd-DTPA)35 was then adminis-
trated at a dose of 0.1 mmol/kg as a bolus through tail vein injection,
and a series of seven postcontrast images were acquired every 6 minutes
for a period of ∼45 minutes. Axial images were collected from at least
two to three slices through the tumor. Whole-body angiography was
acquired using a three-dimensional spoiled gradient recalled echo scan
(matrix size, 192 × 96 × 96; FOV, 4.8 × 3.2 × 3.2 cm; TE, 3.0 milli-
seconds; TR, 15 milliseconds; flip angle, 40°; scan time, = 2 minutes
18 seconds).
After image acquisition, raw image sets were transferred to a work-
station for further processing using the medical imaging software, Ana-
lyze (AnalyzeDirect, Overland Park, KS). The change in R1 (ΔR1) after
contrast agent injection was assumed to be proportional to the tissue
concentration of gadolinium. Linear regression analysis of the change
in R1 (ΔR1) during the 45-minute postcontrast period time was per-
formed to estimate the relative vascular volume (RVV) of DMXAA-
treated and untreated control tumors, and differences were analyzed
for statistical significance [10,15]. R1 maps were calculated on a pixel-
by-pixel basis using MATLAB (Version 7.0; Mathworks, Inc., Natick,
MA) [10,15].
Histology and Immunohistochemistry
Animals from control and treatment groups (n = 3-4 per group)
were killed according to Institutional Animal Care and Use Committee
guidelines, and tissues were harvested for histology and immunohisto-
chemistry. The tumor, along with adjoining muscle, salivary glands,
heart, and liver tissues, was excised to examine the effects of VDA
therapy on tumor and normal tissues. Tissue sections were stained
for the pan endothelial cell adhesionmolecule, CD31, according to pre-
viously described procedures [15]. Briefly, excised tissues were placed in
zinc fixative for 18 hours and subsequently transferred to 70% ethanol,
dehydrated, and embedded in paraffin. Sections 5 μm in thickness were
stained with rat anti–mouse CD31 monoclonal antibody (BD Bio-
sciences, San Jose, CA) at 10-μg/ml concentration for 60 minutes at
37°C. Counterstaining of sections was performed with Harris hema-
toxylin (Poly Scientific, Bay Shore, NY). In place of the primary anti-
body, an isotype match (rat immunoglobulin G 2a also at 10 μg/ml)
was placed on a duplicate slide as a negative control. All slides were read
and interpreted by a board-certified pathologist (K.T.).
Glass slides containing various tissue sections were scanned and digi-
tized using the ScanScope XTsystem (Aperio Technologies, Vista, CA)
Figure 2. Contrast-enhanced MRI of orthotopic HNC xenografts.
Axial T2W images and corresponding pseudocolorized and binar-
ized R1 maps (R1 = 1/T1) of serial slices of an orthotopic FaDu
tumor showing a marked but heterogeneous pattern of enhance-
ment during the postcontrast imaging period. The panels of images
represent R1 maps calculated on a pixel-by-pixel basis from serial
T1W images before (precontrast) and after (post contrast) contrast
agent injection for ∼40 minutes. Arrows indicate tumor; B, brain.
Figure 3. Reduction in vascular volume of orthotopic HNC xeno-
grafts after VDA treatment. (A) Temporal change in R1 (ΔR1) values
of control and DMXAA-treated orthotopic FaDu tumors calculated
during a 40-minute period showing a significant decrease in contrast
agent accumulation between control and treatment groups (P< .001
between slopes). (B) Calculated RVV of untreated control tumors and
DMXAA-treated tumors showed a marked reduction 24 hours after
DMXAA treatment comparedwith untreated controls (P< .05), indic-
ative of significant tumor vascular disruption by DMXAA. No signifi-
cant differences were seen (P > .5) in the calculated ΔR1 values of
murine brain (C) and muscle tissues (D) from animals in the control
and treatment groups.
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through the Pathology Resource Network at Roswell Park Cancer
Institute. Digitized images were then captured using the ImageScope
software (Version 9.1; Aperio Technologies) at a magnification of ×20.
Statistical Analyses
All measured values are reported as mean ± SEM. The 2-tailed t test
was used to compare ΔR1 values of normal tissues (brain, muscle) of
animals between control and treatment groups. P < .05 was considered
statistically significant. All statistical calculations and analyses were
performed using GraphPad Prism (Ver. 5.00 for Windows; GraphPad
Software, San Diego, CA).
Results and Discussion
The overall goal of this study was to examine the potential of anti-
vascular therapy in HNC using the tumor VDA, DMXAA. Unlike
ectopic tumors established beneath the skin, orthotopic tumors are
generally inaccessible to caliper measurement and are often detected
by palpation, typically, only during late stages of tumor growth. The use
of noninvasive imaging techniques such as MRI is therefore essential
for serial (longitudinal) assessment of morphologic and functional
changes associated with tumor progression in vivo. In the present study,
serial anatomic MRI was performed at different times after tumor cell
inoculation to visualize the extent and invasion of orthotopic tumor
growth in vivo. Multislice T2WMR images provided good contrast be-
tween tumor and surrounding normal tissues and allowed distinct de-
lineation of the extent of tumor growth in vivo. Figure 1 shows coronal
and axial T2W MR images of an untreated control mouse bearing
orthotopic FaDu tumor (arrows) on day 13 after transcervical injection
of tumor cells. Tumor volume as measured from the multislice T2W
coronal image was 44.6 mm3. Tumors were established in the floor of
the mouth with invasion into the musculature of the tongue during a
3- to 4-week period. Tumor volumes of untreated orthotopic FaDu
xenografts measured at different times after implantation were as fol-
lows (n = 5): day 7 (33.42 ± 8.0), day 14 (46.60 ± 6.3), day 17
(61.64 ± 13.2), and day 24 (83.40 ± 25.6).
Using noninvasive contrast-enhanced MRI, we then examined the
perfusion characteristics of orthotopic FaDu tumors before treatment.
Contrast-enhancedMRI is a noninvasive technique that provides infor-
mation pertaining to tumor vascular function based on kinetic analysis
of an intravenously administered gadolinium-based contrast agent
[16,17]. The methodology is extensively used in preclinical and clinical
studies to assess tumor response to antiangiogenic and antivascular
therapies [16,17]. Detailed description of the principles and the meth-
odology has been provided by others [16–19]. Using this technique, the
pattern of enhancement in control tumors after administration of an
intravascular MR contrast agent, albumin–Gd-DTPA [20], was visual-
ized in serially acquired T1W images. Figure 2 shows axial T2W images
and corresponding calculated R1 maps of three slices of an orthotopic
FaDu tumor before and after contrast agent administration. Axial T2W
images provided adequate contrast to allow clear delineation of the
tumor margins. R1 maps calculated on a pixel-by-pixel basis before
and after contrast agent injection for ∼40 minutes showed a marked
but heterogeneous pattern of enhancement within the tumor over the
postcontrast imaging period (Figure 2; R1 maps).
To assess the acute changes in vascular function after VDA therapy
in orthotopic HNC xenografts, T1W contrast-enhanced MRI was per-
formed in a separate cohort of tumor-bearing mice (n = 4), 24 hours
after treatment with a single injection of DMXAA (25 mg/kg, intraperi-
toneally) and compared with untreated controls (n = 4 per group). The
change in longitudinal relaxation rate (ΔR1tumor) was calculated over
time in untreated control tumors and DMXAA-treated tumors as an
indirect measure of tissue perfusion. As shown in Figure 3A, a steady
increase in ΔR1tumor (r
2 = 0.86) was observed in untreated control
FaDu xenografts highlighting the permeability of vessels to the contrast
agent during the 40-minute period. In comparison, 24 hours after treat-
ment, minimal increase in ΔR1tumor was observed after contrast agent
injection (r2 = 0.05, P < .001). Linear regression analysis of ΔR1tumor
was then performed to measure the RVVof control and treated tumors
based on the change in R1 postcontrast agent injection and precontrast
T1 (henceR1) values. Previous studies by others andus have demonstrated
that the change in ΔR1 measured over time can be used to RVV (y-
intercept) and permeability (slope) of tumors [15,18,19]. However, in
the present study, linear regression analysis of the temporal change
in ΔR1 over time revealed significant differences between the slopes at
baseline and posttreatment time points. Therefore, individual estimates
of RVV were calculated for each tumor in control and treatment
groups and then analyzed for statistical significance using a 2-tailed t test.
The calculated RVVof control tumors was 0.1513 ± 0.05. In compari-
son, a marked reduction in RVV (0.0060 ± 0.009, P < .05) was observed
24 hours after VDA treatment, indicative of significant tumor vascular
disruption by DMXAA. Analysis of ΔR1 values of murine brain
(Figure 3C) and muscle tissues (Figure 3D) did not show any statistical
difference between control and treatment groups.
R1 maps were also calculated on a pixel-by-pixel basis to visualize
differences in enhancement after contrast agent administration be-
tween untreated control tumors and DMXAA-treated tumors. Pseudo-
colorized and binarized axial R1 maps of a control mouse (left) and
DMXAA-treatedmouse (right) are shown in Figure 4. Before treatment,
Figure 4. Contrast-enhanced MRI of antivascular therapy in HNC.
Pseudocolorized axial R1 maps (top panel), T2W (middle panel), and
three-dimensional angiography (bottom panel) of a control mouse
(left) and DMXAA-treated mouse (right) 24 hours after treatment.
Both R1 maps and three-dimensional images revealed a lack of
enhancement within the tumor after contrast in the DMXAA-treated
animal compared with untreated control. T2W images of the same
animal showed hypointense regions within the tumor 24 hours after
treatment, suggestive of hemorrhage.
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a marked enhancement was visible within the tumor during the 40-
minute period after contrast imaging, indicative of the presence of a
functioning vasculature. In contrast, R1 maps of the tumor calculated
from images acquired after treatment showed no visible enhancement
within the tumor, indicative of treatment-induced reduction in vascular
perfusion at the 24-hour time point (top panel). T2W images of the
same animal also revealed hypointense regions within the tumor, sug-
gestive of hemorrhage compared with the control tumor (middle panel ).
In addition, three-dimensional angiography was performed using a
spoiled gradient echo to confirm DMXAA-induced vascular dam-
age in vivo. Consistent with the R1 maps, three-dimensional spoiled
gradient echo images of the control animal showed considerable en-
hancement after contrast in the tumor. Corresponding images of the
DMXAA-treated animal showed a complete lack of enhancementwithin
the tumor after contrast agent administration confirming tumor vascular
response to DMXAA (lower panel ).
In addition to noninvasive MRI, histology and immunohistochemi-
cal staining of tumor sections for the endothelial cell adhesion molecule,
CD31, were performed to assess vascular damage after treatment. Con-
sistent with our previous observations with subcutaneous FaDu tumors,
orthotopic FaDu xenografts exhibited a poorly differentiated SCC his-
tologic phenotype (Figure 5A). CD31-immunostained tumor sections
of untreated orthotopic FaDu tumors showed distinctly visible CD31+
endothelial cells (Figure 5C ). In sharp contrast, hematoxylin and
eosin (H&E)–stained sections of treated tumors showed multiple
hemorrhagic foci with widespread (>50%) areas of necrosis (Figure 5B).
Minimal areas of viable tumor cells were visible mostly in the periph-
ery. CD31-immunostained sections of tumors obtained from treated
Figure 5. Vascular damage and tumor necrosis after VDA treatment. Panel of digitized images showing tumor (A–D) and normal (E–H)
tissue sections obtained from control and DMXAA-treated animals. Control tumors showed a poorly differentiated SCC phenotype (A)
and appeared well vascularized with distinctly visible CD31+ endothelial cells (C). In sharp contrast, H&E-stained sections of treated
tumors showed widespread areas of necrosis (B). CD31-immunostained sections of tumors obtained from treated animals showed
loss of vessel integrity and extensive vascular damage evidenced by minimal or complete absence of CD31 staining (D). H&E-stained
sections of salivary glands obtained from both control (E) and treated (F) animals showed normal glandular histology with no tissue
necrosis. Corresponding CD31 immunostaining showed no evidence of vascular damage with intact CD31 staining in treated animals
(H) similar to controls (G). Digitized images were captured at an apparent magnification of ×20 using the ImageScope software (Version
9.1; Aperio Technologies).
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animals showed total loss of vessel integrity and extensive vascular
damage evidenced by minimal or complete absence of CD31 staining
(Figure 5D).
To further investigate the selectivity of the vascular disruptive effects
of DMXAA in vivo, normal tissues (salivary glands, mouse liver, and
heart) were also excised for immunostaining and histology. Salivary
glands obtained from both control (Figure 5E) and treated (Figure 5F)
animals showed normal histologic features with intact ductal archi-
tecture and viable glandular cells. No evidence of vascular damage
was observed in salivary gland tissue with intact CD31 staining in
treated animals (Figure 5H ) similar to controls (Figure 5G ). CD31
and H&E staining of murine heart and liver tissues also appeared
normal with no evidence of vascular damage or tissue necrosis (data
not shown).
The vascular disruptive effects of DMXAA have been attributed to
a combination of biologic responses ranging from direct drug effects
on the endothelium to induction of mediators such as tumor necrosis
factor alpha (TNF-α) and serotonin [21]. Although the expression of
these mediators was not investigated in the study, we have recently
demonstrated increased induction of TNF-α in murine fibrosarcomas
after DMXAA treatment [15]. Interestingly, in the previous study, we
did not observe any change in TNF levels inmurine muscle tissue. Con-
sistent with this previous observation, in the present study, peritumoral
skeletal muscle tissue appeared intact with no evidence of vascular dam-
age, further highlighting the selectivity of VDA therapy in the ortho-
topic HNC model.
Solid tumors are dependent on the presence of a functioning vascular
network for their continued growth and differentiation [4,5]. The
structural and functional differences between tumor and normal tissue
vasculature have led to the development of several agents that result in
the selective disruption of tumor-associated blood vessels [22]. These
VDAs target existing tumor vessels and have been shown to result in
vascular shutdown in a variety of preclinical model systems [22 and ref-
erences within]. One such tumor-VDA that is currently undergoing
active clinical evaluation is DMXAA (ASA404). Phase 1 clinical trials
of DMXAA have demonstrated a favorable safety profile of the agent in
patients with evidence of pharmacodynamic activity observed at well-
tolerated doses [23]. Recent, phase 2 trials of the agent in combination
with chemotherapy for lung cancers have also revealed encouraging re-
sults [24]. We have previously reported the activity of DMXAA against
two ectopic HNC xenografts [10]. The results revealed potent anti-
vascular, antitumor activity of DMXAA against both ectopic HNC
xenografts evaluated [10]. However, it is well recognized that the host
microenvironment strongly influences the biologic characteristics of
tumors including cellular differentiation, angiogenesis, and metastatic
potential [11,12]. Therefore, in this study, we examined acute changes
in vascular function after DMXAA treatment in orthotopic FaDu
HNC xenografts. Although both ectopic and orthotopic FaDu tumors
exhibited similar histologic characteristics, an important distinction be-
tween tumors established in the two sites lies in their metastatic ability.
Experimental studies carried out in our laboratory have shown that
orthotopic FaDu tumors exhibit lymph node metastases, whereas sub-
cutaneous tumors do not. This is of particular relevance because head
and neck tumors often exhibit locoregional metastases. However, we
did not perform a systematic examination of the effect of VDA therapy
on nodal metastases, a recognized limitation of the present study.
Nevertheless, we have provided a proof-of-principle demonstration of
the potent vascular disruptive activity of DMXAA in an orthotopic
model of HNC. In addition, our histology/immunohistochemistry
results demonstrate the selectivity in the vascular disruptive effects of
DMXAA in vivo (Figure 5), an issue not entirely addressed our previous
study [10].
It is generally believed that VDAs are likely to result in clinical benefit
only when used in combination with other therapies. In this regard, we
have recently shown that low dose DMXAA potentiates the antitumor
efficacy of photodynamic therapy (PDT) against murine colon tumors
[25]. Although tumor growth inhibition after VDA monotherapy was
not evaluated in the present study, results from our initial studies in-
vestigating the long-term response of orthotopic FaDu xenografts to
PDT-DMXAA combination therapy have revealed a significant delay
in tumor growth after the combination of DMXAA (25 mg/kg) with
HPPH-PDT compared with PDTmonotherapy (Seshadri, personal
communication). The findings of these ongoing studies will be reported
as a separate publication focusing on the potential of antivascular ther-
apy (DMXAA) in the combination setting. Ongoing studies are also
aimed at performing a systematic evaluation of the activity of DMXAA
against patient tumor xenografts established in immunodeficient mice.
Successful completion of such preclinical trials of VDAs using surgical
tumor specimens obtained from HNC patients would provide a strong
rationale and scientific evidence to initiate phase 1 trials of the agent
in HNC.
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